Desloratadine for the treatment of cypress pollen-induced allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 3, 2009, Pages 260-266

  Demoly, Pascal ^a   Dreyfus, Isabelle ^b   Dhivert Donnadieu, Henriette ^a   Mesbah, Kamal ^b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b Schering Plough   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE; PLACEBO; POLLEN ANTIGEN;

ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FRANCE; GASTROENTERITIS; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PEAK NASAL INSPIRATORY FLOW; POLLEN ALLERGY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

EID: 70349446253     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60191-3     Document Type: Article

References (32)

1. Charpin D, Calleja M, Lahoz C, Pichot C, Waisel Y. Allergy to cypress pollen. Allergy. 2005;60:293-301.
2. Di Felice G, Caiaffa MF, Bariletto G, et al. Allergens of Arizona cypress (Cupressus arizonica) pollen: characterization of the pollen extract and identification of the allergenic components. J Allergy Clin Immunol. 1994; 94:547-555. (Pubitemid 24289528)
3. Mistrello G, Roncarolo D, Zanoni D, et al. Allergenic relevance of Cupressus arizonica pollen extracts and biological characterization of the allergoid. Int Arch Allergy Immunol. 2002;129:296-304.
4. Ariano R, Mistrello G, Mincigrucci G, et al. In vitro and in vivo biological activities of old and fresh Cupressus arizonica pollen. J Investig Allergol Clin Immunol. 2006;16:177-182. (Pubitemid 43911059)
5. Bousquet J, Khaltaev N, Cruz AA, et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160. (Pubitemid 351357811)
6. Demoly P, Allaert F-A, Lecasble M, Bousquet J; for PRAGMA (Programme de Recherches Appliquées à la Gestion des Maladies Allergiques). Validation of the classification of ARIA (Allergic Rhinitis and its Impact on Asthma). Allergy. 2003;58:672-675.
7. Ariano R, Passalacqua G, Panzani R, et al. Airborne pollens and the prevalence of pollinosis in western Liguria: a 10-year study. J Investig Allergol Clin Immunol. 1999;9:229-234. (Pubitemid 29447478)
8. Boutin-Forzano S, Gouitaa M, Hammou Y, Ramadour M, Charpin D. Personal risk factors for cypress pollen allergy. Allergy. 2005;60:533-535. (Pubitemid 40332984)
9. Bousquet PJ, Gallega MP, Dhivert-Donnadieu H, Demoly P. Latex is not essential in a standardized skin prick test battery. Allergy. 2005;60:407-408. (Pubitemid 40293362)
10. Fiorina A, Scordamaglia A, Guerra L, Canonica GW, Passalacqua G. Prevalence of allergy to cypress. Allergy. 2002;57:861-862.
11. De Luca A, Graziani E, Anticoli S, Simeoni S, Terzano C, Mannino F. Respiratory allergy to Cupressus sempervirens in Rome. Allergol Immunopathol (Madr). 1997;25:229-232. (Pubitemid 127513473)
12. Papa G, Romano A, Quaratino D, et al. Prevalence of sensitization to Cupressus sempervirens: a 4-year retrospective study. Sci Total Environ. 2001;270:83-87. (Pubitemid 32279595)
13. Aira MJ, Dopaza A, Jato MV. Aerobiological monitoring of Cupressaceae pollen in Santiago de Compostela (NW Iberian Peninsula) over six years. Aerobiologia. 2001;17:319-325.
14. Mandrioli P, De Nuntiis P, Ariatti A, Magnani R. Cypress in Italy: landscape and pollen monitoring. Allerg Immunol (Paris). 2000;31:116-121. (Pubitemid 30224863)
15. Charpin D, Hughes B, Mallea M, Sutra J-P, Balansard G, Vervloet D. Seasonal allergic symptoms and their relation to pollen exposure in southeast France. Clin Exp Allergy. 1993;23:435-439. (Pubitemid 23172597)
16. Aceituno E, Del Pozo V, Mínguez A, et al. Molecular cloning of major allergen from Cupressus arizonica pollen: Cup a 1. Clin Exp Allergy. 2000;30:1750-1758. (Pubitemid 32011755)
17. Schwietz LA, Goetz DW, Whisman BA, Reid MJ. Cross-reactivity among conifer pollens. Ann Allergy Asthma Immunol. 2000;84:87-93.
18. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica: a double blind study. Allergol Immunopathol (Madr). 2001;29:238-244. (Pubitemid 33636525)
19. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104:364-369. (Pubitemid 29420434)
20. Macchia L, Caiaffa MF, Di Paola R, et al. Second generation antihistamines in the treatment of nasal allergic rhinitis due to Parietaria and cypress pollens. Pharmacol Res. 2001;44:461-466. (Pubitemid 34014325)
21. Williams BO, Hull H, McSorley P, Frosolono MF, Sanders RL. Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar. Ann Allergy Asthma Immunol. 1996;76: 432-438. (Pubitemid 26153155)
22. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol. 2006;96:363-368. (Pubitemid 43277178)
23. Simons FER, Prenner BM, Finn A Jr; Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003;111:617-622. (Pubitemid 36337887)
24. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007;62:359-366. (Pubitemid 46398792)
25. Horak F, Stübner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003;58: 481-485. (Pubitemid 36649307)
26. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109:956-1061. (Pubitemid 34634305)
27. Kim K, Sussman G, Hebert J, Lumry W, Lutsky B, Gates D. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96:460-465.
28. de Graaf-in't Veld T, Koenders S, Garrelds IM, Gerth van Wijk R. The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis. J Allergy Clin Immunol. 1996;98:508-513.
29. Pradalier A, Neukirch C, Dreyfus I, Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy. 2007;62:1331-1334. (Pubitemid 47537496)
30. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10: 407-415. (Pubitemid 20025670)
31. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996; 98:843-845. (Pubitemid 26357253)
32. Akerlund A, Andersson M, Leflein J, Lildholdt T, Mygind N. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol. 2005;115:S460-S482. (Pubitemid 40320996)